Navigation Links
Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than Thought
Date:8/4/2008

A paper published in the International Journal of Hematology by scientists from the Fudan-Cinpathogen Clinical and Molecular Research Center at Fudan University, Shanghai, in collaboration with the University of Colorado, and Cincinnati Children's Hospital indicates that specific subtypes of chronic lymphoid neoplasms are not as rare in China as has been previously reported. Diagnosis and classification were performed by a single central laboratory in Shanghai according to WHO (2001) criteria making it largest prospective case series of lymphoid neoplasms in China published to date.

Shanghai, China (PRWEB) August 4, 2008 -- http://www.springerlink.com/content/r1623x466m24237r/ [A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China] published online in the International Journal of Hematology shows significant differences in frequency of subtypes of lymphoma and other lymphoid neoplasms between China and the West. The report also reveals that chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), previously thought to be rare in China, is more common than suggested in earlier reports.

This publication is eighth in a series reporting research conducted by Cinpathogen scientists in collaboration with Fudan University, the University of Colorado, and Cincinnati Children's Hospital, that characterizes the features and frequency of hematopoietic disorders in China.

"Our study has increased medical knowledge and allowed us to help individual patients by sharing technological advancements," said Dr. Richard D. Irons, Cinpathogen CEO and the principal investigator of the project. "We are obtaining a better understanding of the prevalence of hematopoietic diseases in China, while at the same time having an impact on people's lives by providing the citizens of Shanghai the same advanced diagnostics that patients at modern Western medical centers receive."

A unique aspect of the 4 year Shanghai study is that diagnosis and classification were performed by a single central laboratory according to WHO (2001) criteria. This month's publication presents the results of the largest prospective case series of lymphoid neoplasms in China published to date. "It serves as an example that high-quality, state-of-the-art research is possible in China," explained Dr. Irons.

Cinpathogen operates the Fudan-Cinpathogen Clinical and Molecular Research Center providing diagnostics to patients from over 30 Shanghai area hospitals and conducting translational research on hematopoietic and lymphoid disorders in China. The Center offers specialized clinical capabilities that meet Western standards in the fields of hematology, molecular pathology, cytogenetics and flow cytometry.

For more information, visit http://www.cinpathogen.com [Cinpathogen's website] or contact our Boulder, Colorado ( 303-381-2543) or Shanghai ( 86-21-5423-7760) offices.

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1167414.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: